New Triple-Threat treatment tested for tough bladder cancer
NCT ID NCT04863885
Summary
This study is testing a combination of three drugs—ipilimumab, nivolumab, and sacituzumab govitecan—as a first treatment for advanced bladder cancer that has spread. It is for patients who are not eligible for the standard chemotherapy drug cisplatin. The first part of the study aims to find the safest and most effective dose, and the second part will measure how well the combination shrinks tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.